Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Valley National Advisers Inc.

Valley National Advisers Inc. decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 19.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,093 shares of the biopharmaceutical company's stock after selling 9,062 shares during the quarter. Valley National Advisers Inc.'s holdings in Gilead Sciences were worth $3,517,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in GILD. Avior Wealth Management LLC boosted its stake in Gilead Sciences by 1.2% during the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock valued at $782,000 after buying an additional 108 shares during the period. Southland Equity Partners LLC lifted its stake in Gilead Sciences by 3.6% during the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock worth $289,000 after purchasing an additional 110 shares during the last quarter. Concord Asset Management LLC VA lifted its stake in Gilead Sciences by 3.8% during the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock worth $256,000 after purchasing an additional 111 shares during the last quarter. Berkshire Bank lifted its stake in Gilead Sciences by 3.4% during the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock worth $314,000 after purchasing an additional 111 shares during the last quarter. Finally, TFB Advisors LLC lifted its stake in Gilead Sciences by 1.2% during the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company's stock worth $788,000 after purchasing an additional 116 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on GILD. Truist Financial lifted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a report on Friday, November 8th. Maxim Group downgraded Gilead Sciences from a "buy" rating to a "hold" rating in a report on Friday, November 8th. Robert W. Baird lifted their price objective on Gilead Sciences from $80.00 to $95.00 and gave the stock a "neutral" rating in a report on Thursday, November 7th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Finally, The Goldman Sachs Group lifted their price objective on Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $98.39.

Gilead Sciences Trading Up 1.7 %

NASDAQ GILD traded up $1.62 during trading hours on Wednesday, hitting $99.61. 5,151,513 shares of the company were exchanged, compared to its average volume of 6,888,638. The stock has a 50-day moving average price of $92.71 and a 200 day moving average price of $86.32. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $100.51. The stock has a market cap of $124.14 billion, a PE ratio of 1,107.07, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.29 earnings per share. Analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock worth $53,611,715 over the last 90 days. Company insiders own 0.29% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.